Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Pilots First Provincial Fast-Track Regulation To Cover More Innovative Drugs

This article was originally published in PharmAsia News

Executive Summary

Drugs from multinationals could be eligible under the new program, experts say.

You may also be interested in...



China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals

SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process

China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference

SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

UsernamePublicRestriction

Register

SC080460

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel